Under the hood of Novo Holdings’ capital investment strategy

Novo Holdings’ Morten Beck Jørgensen talks about reinvesting the large inflows from Novo Nordisk, ensuring alignment of interest with external managers and companies and its philosophy of focusing on the underlying fundamentals.

Many Nordic institutional investors are reaping the rewards of being a shareholder in the Danish pharmaceutical giant Novo Nordisk, which last year became Europe’s most valuable company following the successes of its weight-loss and diabetes drugs Wegovy and
Please read our articles. Do become a member.